Onswik Wins FDA Approval but Enters a Duopoly: Commercial Execution Now Decides the Race

FDA Clears Eli Lilly's Weekly Insulin Onswik for Type 2 Diabetes

Eli Lilly's weekly insulin, Onswik (insulin efsitora alfa-gobe), has received FDA approval for the treatment of type 2 diabetes in the U.S., marking its fourth global clearance after Europe, Mexico, and Japan. This approval positions Lilly to intensify its rivalry with Novo Nordisk, which also has a once-weekly insulin, Awiqli, approved earlier this year. Onswik was evaluated in the Phase 3 QWINT clinical trials, involving 3,400 adults, demonstrating non-inferiority to standard once-daily insulin options like insulin glargine and insulin degludec. Specifically, the QWINT-2 trial showed Onswik reduced A1C levels by 1.34%, compared to a 1.26% reduction with degludec. Lilly plans to make Onswik available in the U.S. in the coming months, offering patients the potential for over 300 fewer injections annually.

• Onswik's U.S. FDA approval is a significant regulatory achievement, following prior clearances in Europe, Mexico, and Japan. This strategic approval enables Eli Lilly to directly compete with Novo Nordisk in the rapidly evolving weekly insulin market. With Novo Nordisk's Awiqli already approved in March, Onswik's entry intensifies the competition, offering patients with type 2 diabetes an alternative weekly treatment that could substantially reduce the burden of daily injections, enhancing convenience and adherence.
• The efficacy of Onswik was established through the comprehensive Phase 3 QWINT clinical trials, which enrolled 3,400 adults with type 2 diabetes. These trials successfully demonstrated Onswik's non-inferiority when compared to existing standard-of-care once-daily insulin treatments, including insulin glargine and insulin degludec. Notably, the QWINT-2 trial specifically reported that Onswik achieved a 1.34% reduction in A1C, a key indicator of long-term blood sugar control, closely matching the 1.26% reduction seen with degludec.
• The approved label for Onswik includes critical safety information, specifically advising against its use in patients with type 1 diabetes due to an elevated risk of hypoglycemia, or low blood sugar. This cautionary guidance is vital for appropriate patient selection and mirrors similar warnings found on the label of competitor products like Awiqli. Healthcare providers must adhere to these guidelines to ensure patient safety and optimize treatment outcomes, emphasizing the importance of distinguishing between type 1 and type 2 diabetes for this therapy.

Addressing the Burden of Daily Injections in Type 2 Diabetes

Managing type 2 diabetes remains a multifaceted challenge, with barriers operating simultaneously at the patient, provider, and health system levels. Current pharmacological advances have not fully resolved the clinical and operational gaps that limit optimal glycaemic control across diverse care settings.

• Therapeutic inertia is a significant and prevalent barrier to treatment optimisation. Evidence from Indian primary care settings indicates that delays in treatment intensification are driven by patient-related factors (fear, lack of awareness), provider-related factors (clinical conservatism), and system-level constraints (resource limitations). In a low-income outpatient setting in Ethiopia, therapeutic inertia was observed in 58.7% (95% CI: 52.3%–65.4%) of cases of uncontrolled hypertension, with physician-reported rationales including "BP being close to the target value" (AOR = 6.074; 95% CI: 1.315–28.060) and "concerns about patient adherence" (AOR = 5.487; 95% CI: 1.061–28.362) as positively associated factors.

• Beta-cell function decline is a core pathophysiological challenge, though evidence suggests it is not universally progressive or irreversible. In morbidly obese subjects with T2DM, fasting C-peptide (FCPEP), the insulinogenic index (CRCPEP/CRG), and insulin sensitivity (FCPEP × FG) improved markedly (P < 0.001) following weight loss and oral agent therapy, indicating that declining beta-cell function may be reversible upon improving insulin sensitivity and eliminating exogenous insulin inhibition.

• Gastrointestinal tolerability limits the use of GLP-1 receptor agonists, a cornerstone of second-line T2DM therapy. Nausea and vomiting are the dominant side effects across the GLP-1RA class; with semaglutide, these diminished over time during continuous treatment, but remain a barrier to initiation and adherence. For the dual GIP/GLP-1 agonist RG7697, tolerability was limited by gastrointestinal adverse events at the highest dose (5 mg), with a small dose-dependent increase in heart rate also observed.

• Safety signals requiring ongoing vigilance complicate treatment selection. An unexpected increase in diabetes-related retinopathy was observed in the SUSTAIN 6 cardiovascular outcome trial of semaglutide, leading to a warning in the Summary of Product Characteristics (SmPC) concerning treatment in patients with pre-existing retinopathy. The mechanism remains unelucidated but may relate to a nonspecific effect of rapid glycaemic reduction in patients with pre-existing retinopathy and high baseline HbA1c.

• Medication regimen complexity and adherence present compounding challenges, particularly in high-risk subgroups. In a cross-sectional study of internal medicine outpatients, only 44% of participants demonstrated perfect adherence to therapy. Complexity scores related to dosing schedule and instructions for use were especially higher in patients with hypertension or diabetes, and geriatric patients and recently hospitalised patients were less likely to fully adhere to therapy (P = 0.030 and P = 0.040, respectively).

Onswik's Clinical Profile: Efficacy and Safety from QWINT Trials

Recent clinical evidence across a range of interventions highlights meaningful advances in glycemic control, weight reduction, and cardiometabolic risk management in type 2 diabetes mellitus (T2DM). The studies below span pharmacological and lifestyle-based approaches, reflecting the breadth of current therapeutic investigation.

• Low-Energy Total Diet Replacement (TDR) Trial (ISRCTN21335883) — Intervention: Low-energy total diet replacement vs. standardized dietetic care in insulin-treated T2DM patients. Mean weight loss at 12 months was 9.8 kg (SD 4.9) in the TDR group versus 5.6 kg (SD 6.1) in controls (adjusted mean difference −4.3 kg; 95% CI −6.3 to −2.3; p<0.001). Insulin therapy was discontinued in 39.4% of TDR completers versus 5.6% of controls. Insulin requirements fell by 47.3 units (SD 36.4) in the intervention arm versus 33.3 units (SD 52.9) in controls (−18.6 units; 95% CI −29.2 to −7.9; p=0.001). HbA1c fell significantly in the intervention group (4.7 mmol/mol; p=0.02), and quality of life improved by 11.1 points (SD 21.8) versus 0.71 points (SD 19.4) in controls (8.6 points; 95% CI 2.0 to 15.2; p=0.01).

• GLP-1 RA Cardiorenal Network Meta-Analysis (2025) — Intervention: Injectable GLP-1 receptor agonists (efpeglenatide, albiglutide, semaglutide, dulaglutide, liraglutide) in T2DM. Across 15 randomized trials enrolling more than 90,000 participants, efpeglenatide ranked highest for both MACE reduction (OR: 0.74; 95% CI: 0.62–0.87; SUCRA: 81.5%) and renal composite outcomes (OR: 0.68; 95% CI: 0.57–0.81; SUCRA: 81.33%). Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant cardiorenal benefits, albeit with lower rankings. No major inconsistency or publication bias was detected.

• Tirzepatide Real-World Study in Indian Adults (2026) — Intervention: Tirzepatide (dual GIP/GLP-1 receptor agonist) in Indian adults with T2DM. In 71 patients followed for 12 weeks, mean HbA1c decreased from 8.7 ± 1.4% to 6.9 ± 1.0% (mean change −1.8 ± 1.2%; p<0.001), with 59.2% achieving HbA1c <7%. Mean body weight declined by 4.7 ± 3.2 kg (5.7%; p<0.001). Significant improvements were observed in systolic blood pressure (−5.6 mmHg), total cholesterol (−16.6 mg/dL), LDL-cholesterol (−12.2 mg/dL), HDL-cholesterol (+2.6 mg/dL), triglycerides (−46.4 mg/dL), and liver enzymes (all p<0.001). Gastrointestinal adverse events occurred in 59.2% of patients (predominantly mild to moderate), and the treatment discontinuation rate was 22.2%, driven primarily by gastrointestinal intolerance (36%) and financial constraints (32%).

• eHealth Lifestyle Coaching RCT — Denmark (2022) — Intervention: Primary care-anchored eHealth lifestyle coaching programme vs. standard care in T2DM patients with BMI 30–45 kg/m². At six months, mean body weight loss was 4.2 kg (95% CI −5.49; −2.98) in the intervention group versus 1.5 kg (95% CI −2.57; −0.48) in controls (p=0.005). Among patients with elevated HbA1c at baseline, 39% (24/62) in the intervention group achieved a normalized HbA1c <6.5% at six months, compared with 20% (8/40) in the control group (p=0.047).

Navigating the Evolving Weekly Insulin Landscape for Type 2 Diabetes

The past several years have seen a marked expansion in the therapeutic options available for type 2 diabetes, driven by robust trial data across multiple drug classes. SGLT2 inhibitors have consolidated their position as cardiorenal protective agents: post hoc analysis of the EMPA-REG OUTCOME® trial demonstrated that empagliflozin significantly reduced the risk of eGFR decline across multiple thresholds, with hazard ratios ranging from 0.81 (95% CI 0.72–0.91) for a ≥30% eGFR decline composite to 0.37 (95% CI 0.23–0.61) for a ≥57% eGFR decline composite, each combined with initiation of renal replacement therapy or renal death. A retrospective cohort study in Chinese adults with obesity and type 2 diabetes further corroborated these findings in a real-world setting, reporting significant improvements in eGFR, serum creatinine, systolic and diastolic blood pressure, HbA1c, and body weight over six months of empagliflozin therapy, with MACE occurring in 8.4% of patients and progression to end-stage renal disease in 1.0%.

GLP-1 receptor agonists have similarly demonstrated durable cardiovascular and renal benefits, and emerging evidence now addresses their use in combination with SGLT2 inhibitors. A systematic review and meta-analysis of randomized placebo-controlled trials found that GLP-1 receptor agonists reduced the risk of MACE by 21% (HR 0.79, 95% CI 0.71–0.87), with consistent effects regardless of baseline SGLT2 inhibitor use (P-heterogeneity=0.78). Effects on the composite kidney outcome (RR 0.79, 95% CI 0.66–0.95) and eGFR slope (0.78 mL/min/1.73m²/year, 95% CI 0.57–0.98) were likewise unaffected by concomitant SGLT2 inhibitor use. A separate meta-analysis of 18 cohort studies (1,164,774 participants) found that combination SGLT2 inhibitor and GLP-1 RA therapy was associated with lower risk of MACE (RR 0.56, 95% CI 0.43–0.71), all-cause mortality (RR 0.50, 95% CI 0.40–0.63), cardiovascular mortality (RR 0.26, 95% CI 0.16–0.43), hospitalisation for heart failure (RR 0.67, 95% CI 0.64–0.71), and the kidney composite endpoint (RR 0.48, 95% CI 0.32–0.73) relative to monotherapy with either agent, though certainty of evidence was rated low to very low.

Within the GLP-1 RA class, both established and novel agents continue to generate clinically meaningful data. Semaglutide's SUSTAIN and PIONEER trials demonstrated significant reductions in HbA1c, body weight, and MACE, while the STEP trials reported weight loss of up to 20% alongside improvements in obesity-related comorbidities. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed in the SURPASS-5 randomized clinical trial that addition to titrated insulin glargine produced mean HbA1c reductions of −2.11%, −2.40%, and −2.34% at the 5 mg, 10 mg, and 15 mg doses respectively, versus −0.86% with placebo, alongside body weight reductions of −5.4 kg, −7.5 kg, and −8.8 kg versus a gain of 1.6 kg with placebo. Real-world data from Indian clinical practice (n=71) further showed a mean HbA1c reduction of −1.8 ± 1.2% and body weight decline of 4.7 ± 3.2 kg at 12 weeks, with 59.2% achieving HbA1c <7%, though a treatment discontinuation rate of 22.2%—driven primarily by gastrointestinal intolerance (36%) and financial constraints (32%)—underscores the practical barriers to uptake in cost-sensitive healthcare environments. At the frontier of innovation, PG-102, a bispecific GLP-1/GLP-2 Fc fusion protein, demonstrated in a phase 1 multiple ascending dose study that treatment-emergent adverse events occurred in 83.3% of PG-102 participants versus 66.7% on placebo, with no serious adverse events or discontinuations, positioning dual GLP-1R/GLP-2R engagement as a mechanistically distinct incretin strategy warranting further investigation.

Lilly's Weekly Insulin: A New Era for Type 2 Diabetes Management

The FDA approval of Eli Lilly's once-weekly insulin, Onswik, represents a pivotal moment in the management of type 2 diabetes. For years, the daily injection burden of basal insulin has been a significant hurdle, impacting patient adherence and, consequently, glycemic control. Onswik directly addresses this challenge by offering a simplified regimen, promising over 300 fewer injections annually. This shift towards less frequent administration is not merely about convenience; it's about empowering patients to better manage their chronic condition with a therapy that integrates more seamlessly into their lives.

Clinical trials have robustly demonstrated Onswik's efficacy, showing non-inferiority to established daily basal insulins in achieving comparable HbA1c reductions and glycemic control. This clinical validation, coupled with a generally reassuring safety profile regarding hypoglycemia in type 2 diabetes, positions Onswik as a compelling alternative. However, as with any novel therapy, a nuanced understanding of its profile is crucial. Some analyses suggest a slightly higher incidence of total treatment-emergent adverse events compared to daily insulins, and the long-term data on durability and cardiovascular outcomes are still evolving. Furthermore, while highly effective in type 2 diabetes, the safety profile observed in studies for type 1 diabetes differs, underscoring the importance of clear communication regarding its approved indication.

This approval also ignites a new front in the competitive landscape, with Lilly now directly vying with Novo Nordisk in the weekly insulin space. The race to capture market share will likely focus on patient and physician education regarding the benefits of reduced injection frequency, while also addressing any lingering questions about long-term data. Ultimately, the introduction of Onswik signifies a patient-centric evolution in diabetes care, offering a valuable new option that could significantly improve adherence and outcomes for millions living with type 2 diabetes.